The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by CymaBay Therapeutics, in adults for the treatment of a liver illness called primary biliary cholangitis (PBC), including pruritus. It works by controlling liver problems in the body and making the liver less inflamed
Seladelpar belongs to a group of medicines called peroxisome proliferator-activated receptor delta agonists. The medicine can only be prescribed to adult patients with PBC, including pruritus, in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
Drug acquired by Gilead
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze